← Back to Search

Germline Genetic Testing for Myeloid Leukemia

N/A
Waitlist Available
Led By Christopher Reilly, MD
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Age of 18 years or older
* Participants must have histologically confirmed myeloid malignancy OR bone marrow failure within the last 6 months prior to screening.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 63 months
Awards & highlights

Summary

This research study is evaluating the feasibility of conducting cancer genetic testing using healthy skin cells among participants with a diagnosis of a blood cancer. Additionally, investigators will evaluate how often participants with blood cancers are found to have risk for cancer based on family genes.

Who is the study for?
This trial is for individuals diagnosed with blood cancers like myeloid leukemia. It aims to find out if their cancer risk comes from family genes by using a genetic test on healthy skin cells.
What is being tested?
The study is testing the feasibility of using a genetic blood test on skin cells to detect predisposition to myeloid malignancies and other related blood cancers in patients.
What are the potential side effects?
Since this trial involves only a genetic blood test, there are minimal side effects expected, primarily related to the procedure of collecting skin cells which may include slight pain or bruising.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 63 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 63 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Genetic Testing Completion Rate
Incidence Rate of Positive Genetic Results
Secondary study objectives
Detection Rate of Germline Predisposition
Impact of Genetic Results on Clinical Decision-Making
Multidimensional Impact of Cancer Risk Assessment (MICRA) Score
+5 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Germline Genetic TestingExperimental Treatment1 Intervention
Participants will be enrolled and will complete study procedures as follows: * Baseline visit with educational video and questionnaires. * Skin punch biopsy. * Genetic testing results. * Surveys and questionnaires. * Follow up via medical records for up to 2 years from time of study consent.

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor
1,090 Previous Clinical Trials
343,522 Total Patients Enrolled
Christopher Reilly, MDPrincipal InvestigatorDana-Farber Cancer Institute
3 Previous Clinical Trials
151 Total Patients Enrolled
~133 spots leftby Jul 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top